TXA127
Sponsors
Tarix Pharmaceuticals, Columbia University, Sean Collins
Conditions
AnemiaCOVID-19Cord Blood TransplantCoronavirus InfectionHematologic MalignanciesHematologic MalignancyHodgkin DiseaseInherited Metabolic Disease
Phase 1
Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
TerminatedNCT01362036
Start: 2011-04-30End: 2012-04-30Updated: 2016-08-31
Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)
CompletedNCT01543971
Start: 2009-12-31End: 2010-03-31Updated: 2016-08-31
Phase 2
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
CompletedNCT00771810
Start: 2008-10-31End: 2011-12-31Updated: 2017-11-13
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
TerminatedNCT01121120
Start: 2010-06-30End: 2020-12-31Updated: 2020-12-08
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
WithdrawnNCT01554254
Start: 2012-03-31Updated: 2016-08-31
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation
WithdrawnNCT01882374
Start: 2013-12-31End: 2013-12-31Updated: 2016-08-31
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
WithdrawnNCT01882387
Start: 2013-12-31End: 2013-12-31Updated: 2016-08-31
TXA127 for the Treatment of Severe COVID-19
CompletedNCT04401423
Start: 2021-02-10End: 2021-06-10Updated: 2022-07-27
Novel Experimental COVID-19 Therapies Affecting Host Response
CompletedNCT04924660
Start: 2021-07-15End: 2023-12-31Updated: 2025-01-22